The Mounjaro 2.5mg Pen Explained: Starter Dose, Not a Small Dose

The biggest misconception: the starter pen is 'weak'

A question our prescribers hear most weeks is whether the 2.5mg pen is too low a dose to do anything meaningful. It's an understandable worry. The number looks small alongside the 10mg or 15mg strengths that clinical trial results are often quoted from. The reality is that the 2.5mg pen is doing exactly what it's designed to do: preparing your body for treatment rather than delivering peak therapeutic effect from day one.

Tirzepatide slows gastric emptying and amplifies fullness signals through two gut-hormone receptors — GIP and GLP-1. Starting that mechanism at full intensity would leave most people feeling significantly unwell. The starter dose reduces that risk. The NHS medicines page for tirzepatide explains this dose-escalation rationale clearly, and the same logic is built into the licensed schedule from Eli Lilly.

So if you inject the 2.5mg Mounjaro pen for your first four weeks and feel only modest changes to your appetite, that is expected. The pen is working. The therapeutic milestones come as the dose rises. Treating week one as a disappointment is the wrong frame; treat it as the foundation.

What the 2.5mg pen contains and how to use it

Each Mounjaro 2.5mg KwikPen holds four doses: one per week for four weeks. It is a pre-filled, single-use device injected subcutaneously, meaning into the fatty tissue just beneath the skin. Suitable sites are the abdomen, the front of the thigh, or the upper arm. Rotating the site each week reduces localised irritation.

The pen stays in the fridge between uses, stored at 2–8°C. For the precise room-temperature storage window, the rules around what happens if the fridge is unavailable, and the exact injection steps, the Mounjaro SmPC on the eMC is the definitive reference, and the Patient Information Leaflet inside the box walks through every step with diagrams. Prescribers and aftercare teams are there if anything is unclear, but the leaflet should always be your first stop for technique questions.

Once you have worked through the 2.5mg pen, your prescriber reviews how you tolerated it before moving up to the 5mg strength. That review is a clinical step, not a formality. If you had significant side effects, the prescriber might extend the time at 2.5mg. If things went smoothly, titration proceeds on schedule.

Side effects to know about at the starter dose

The most commonly reported effects at any stage of Mounjaro treatment are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These tend to be most noticeable in the first week or two after starting or after a dose increase. At 2.5mg they are usually milder than at higher strengths, which is precisely the point of beginning there.

Injection-site reactions, headache, and fatigue are also reported. Most people find these effects settle within a fortnight. If they persist or are severe, contact the prescriber rather than adjusting anything independently. For context on what to expect after that very first injection, that page covers the first-week picture specifically.

Pancreatitis is a less common but more serious possibility: in January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Any suspected side effects can be reported through the MHRA Yellow Card scheme.

Who receives a 2.5mg pen, and what comes next

Everyone beginning Mounjaro treatment starts at 2.5mg, regardless of their weight or target dose. The licensed schedule is fixed at that entry point. Private eligibility broadly follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the full clinical picture, BMI alone does not determine suitability.

For a broader look at the treatment, the Mounjaro overview page covers the full dose range, the trial evidence, and how the medicine fits into a weight-management plan. If you want to understand how 2.5mg of Mounjaro translates into the volume you actually inject, that page breaks it down clearly. If you want to understand how cost varies across the treatment course, the context around Eli Lilly's UK pricing is worth reading before you start comparing providers. And when you're ready to take the next step, you can check your eligibility with our prescribers, it's a free consultation, reviewed the same day.